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L E T T E R  T O  T H E  E D I T O R
Intravenous immunoglobulin treatment in a type 3 von 
Willebrand disease patient with alloantibodies and a  
life‐threatening gastrointestinal bleed
Dear	Editor,
Alloantibody	development	against	von	Willebrand	 factor	 (VWF)	 is	
a	 rare	 treatment	 complication	 in	 von	Willebrand	 disease	 (VWD).	
Alloantibodies	have	been	encountered	mainly	in	type	3,	the	most	se-
vere	form	with	absent	VWF,	and	particularly	in	null	mutation	cases.1 
Patients	 who	 develop	 alloantibodies	 become	 suddenly	 unrespon-
sive	to	VWF	therapy.	Re‐exposure	to	VWF‐containing	products	can	
also	induce	immune	complex–mediated	complement	activation	and	
life‐threatening	anaphylactic	reactions.2	Intravenous	immunoglobu-
lin	(IVIG)	is	used	in	acquired	von	Willebrand	syndrome	(AVWS),	but	
there	is	lack	of	data	of	IVIG	treatment	in	inherited	VWD‐associated	
alloantibodies.3	Here,	we	report	a	case	of	a	49‐year‐old	woman	with	
type	3	VWD	and	VWF	alloantibodies.	Our	management	of	her	life‐
threatening	gastrointestinal	(GI)	bleed	succeeded	by	co‐administra-
tion	of	IVIG	with	VWF	replacement.
Our	 patient	 had	 extended	 mucocutaneous	 bleeds	 postnatally	
and	was	diagnosed	at	the	time	in	the	1960s	with	‘vascular	haemo-
philia’.	 Inherited	 bleeding	 disorder	 was	 suspected	 early	 on,	 as	 an	
older	sister	died	due	to	a	bleeding	complication	at	the	age	of	2	years.	
Type	3	VWD	diagnosis	was	confirmed	in	the	1970s.	The	patient	re-
ceived	cryoprecipitate	for	ovarian	cyst	bleeds	at	the	age	of	20	and	
21,	 and	prior	 to	 an	 appendectomy	at	 the	 age	of	30	without	 com-
plications.	Alloantibody	first	appeared	when	the	patient	was	giving	
birth	at	the	age	of	35.	At	the	time,	therapy	with	cryoprecipitate	was	
initially	effective	and	continued	for	10	days	postpartum.	However,	
at	8	days	postpartum,	following	cryoprecipitate	infusion,	she	had	an	
allergic	reaction	with	rash	and	fever.	Simultaneously,	VWF	response	
in	the	laboratory	vanished,	but	without	haemostatic	problems.	Two	
years	 later,	 the	 next	 delivery	 was	 handled	 with	 plasma‐derived	
VWF/FVIII	concentrate	(pdVWF/FVIII,	2.4:1	ratio,	Haemate®,	CSL	
Behring)	 without	 allergic	 reactions.	 Again,	 at	 6	 days	 postpartum,	
VWF	response	after	replacement	disappeared,	but	haemostasis	was	
conserved	by	increasing	Haemate®	doses.	At	the	age	of	41,	a	tooth	
extraction	was	managed	successfully	by	a	single	Haemate®	infusion.
The	first	severe	GI	bleeding	episode	occurred	at	the	age	of	46	
in	a	local	hospital	prior	to	patient	referral	into	our	centre.	Due	to	
melaena	with	anaemia	and	with	a	family	history	of	colorectal	can-
cer,	the	patient	underwent	a	colonoscopy.	Tubulovillous	adenoma	
with	mild	dysplasia	was	resected	under	Haemate®	combined	with	
a	monoclonal	antibody‐purified	pdFVIII	to	increase	FVIII	content	
(Amofil®,	manufactured	with	the	method	M,	Sanquin)	prophylaxis.	
This	treatment	approach	had	been	successful	in	managing	another	
Finnish	 type	 3	 patient	 with	 alloantibodies.	 Following	 the	 colo-
noscopy,	 the	patient	developed	prolonged	GI	bleeding,	 receiving	
replacement	with	Haemate®	and	Amofil®	concentrates,	and	red	
blood	cell	 (RBC)	 transfusions.	The	bleeding	ceased	after	21	hos-
pital	days.	Subsequently,	she	was	referred	to	our	comprehensive	
care	centre	for	regular	follow‐up.
Laboratory	 results	 at	 our	 centre	 demonstrated	 absent	 VWF	
(VWF:Ag	and	VWF:RCo	below	the	sensitivity	of	these	assays)	and	
low	FVIII	(2	IU/dL).	DNA	analysis	of	the	VWF	revealed	a	homozygous	
nonsense	null	mutation	c.4975C	>	T	(p.R1659X)	in	exon	28.4	During	
3	years	of	follow‐up,	the	patient	had	only	minor	bleeding	problems	
and	managed	with	tranexamic	acid	(TXA).	She	had	stable	hyperten-
sion	on	a	diuretic,	and	menorrhagia	was	controlled	with	oestrogen	
therapy.
At	 the	age	of	49,	 a	 control	 colonoscopy	was	performed	 in	our	
hospital,	leading	to	the	severe	bleeding	episode	reported	here.	The	
procedure	 was	 decided	 to	 be	 managed	 with	 a	 different	 pdVWF/
FVIII	 concentrate	 than	 previously,	 Wilate®	 (Octapharma),	 due	 to	
the	higher	FVIII	ratio	(VWF/FVIII	1:1).	The	patient	received	a	dose	
of	40	IU/kg	of	Wilate®	prior	to	the	colonoscopy	on	day 1	(Figure	1),	
during	which	6	minor	polyps	 (later	confirmed	benign	hyperplastic)	
were	 resected	 with	 satisfactory	 primary	 haemostasis.	 Wilate®	
(20	 IU/kg)	 replacement	 therapy	 was	 continued	 twice	 daily	 for	 2	
postoperative	 days	with	 good	 laboratory	 response.	On	day 3,	 the	
patient	was	discharged	from	the	hospital	without	bleeding	signs.
However,	on	her	way	home	at	the	train	station,	an	acute	lower	
GI	bleed	started,	and	she	returned	to	the	hospital	in	the	evening	of	
day 3.	The	Wilate®	therapy	was	restarted	with	a	bolus	of	40	IU/kg,	
followed	by	20	IU/kg	every	8	hours.	During	hospital	days 3 to 6,	de-
spite	good	VWF	and	FVIII	levels,	the	GI	bleed	persisted.	In	addition	
to	factor	concentrate,	she	received	daily	RBC	transfusions	aiming	at	
haematocrit	above	30%,	and	platelet	transfusions	to	substitute	her	
defective	platelet	VWF.
On day 7,	 the	 response	 to	 therapy	was	suddenly	 lost	 (no	mea-
surable	VWF	or	FVIII,	Figure	1).	At	the	same	time,	the	GI	bleeding	
worsened,	with	 severe	melaena	10	 times	 and	1700	mL	daily.	 This	
was	considered	to	represent	the	appearance	of	a	VWF	inhibitor,	and	
the	 patient	 was	 transferred	 to	 the	 intensive	 care	 unit.	 Treatment	
with	 rFVIIa	 (NovoSeven®,	 Novo	 Nordisk,	 at	 9.6	 mg	 [109	 µg/kg])	
every	 2	 hours	 was	 initiated	 to	 replace	Wilate®.	 To	 achieve	 local	
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haemostasis,	 a	 control	 colonoscopy	was	 performed	 on	 day 7,	 dis-
covering	bleeding	from	multiple	biopsy	sites.	In	a	difficult	procedure	
with	poor	 local	haemostasis,	 these	sites	were	treated	with	7	clips.	
On	day	8,	with	the	uncontrolled	GI	bleed	continuing,	a	combination	
therapy	 of	Haemate®	 (increasing	 doses	 from	 27/11	 to	 81/33	 IU/
kg)	and	Amofil®	(33	IU/kg)	was	initiated,	with	the	experience	that	
this	 treatment	 had	 resolved	 the	 previous	 GI	 bleeding	 episode.	
Haemate®	and	Amofil®	were	administered	4‐6	times	daily,	alternat-
ing	with	rFVIIa	at	6‐8	times	daily.	RBC	transfusions	were	continued	
(daily	4‐6	units),	and	platelets	and	fresh	frozen	plasma	(Octaplas®,	
Octapharma)	were	also	administered.	She	tolerated	therapies	with-
out	allergic	or	 thrombotic	 reactions.	Transient	VWF	response	was	
observed	day 9,	but	the	bleed	continued.
On day 10,	 a	 new	 control	 colonoscopy	 was	 performed,	 and	 a	
single	 active	 site	 was	 clipped.	 However,	 haemoglobin	 levels	 were	
not	 maintained,	 and	 on	 day 11,	 without	 measurable	 response	 to	
VWF	or	FVIII,	we	infused	IVIG	at	1g/kg	(90	g,	Nanogam®,	Sanquin).	
Importantly,	VWF	and	FVIII	 levels	were	 immediately	 restored	 in	a	
few	hours	after	the	infusion,	and	rFVIIa	was	halted	(Figure	1).	The	GI	
bleed	finally	ceased,	and	the	patient	was	transferred	back	to	the	reg-
ular	ward.	Therapy	with	Haemate®	and	Amofil®	was	continued,	and	
IVIG	administered	every	24	hours	4	times.	After	the	fourth	infusion,	
when	VWF:RCo	suddenly	reached	200	IU/dL,	IVIG	was	stopped.	The	
positive	effect	of	IVIG	infusions	on	VWF	and	FVIII	lasted	for	2	days.
Although	 the	GI	 bleed	 stopped,	 hospitalization	was	 prolonged	
due	to	epistaxis	occurring	on	day 13,	which	was	treated	by	poste-
rior	 tamponation.	 The	 epistaxis	 recurred	 after	 the	 removal	 of	 the	
tamponade	on	day 17,	and	two	more	 IVIG	 infusions	were	adminis-
tered.	The	impact	on	VWF	and	FVIII	levels	was	again	immediate	and	
enough	to	control	the	bleed.	Finally,	the	patient	was	discharged	from	
the	hospital	at	day 20.
The	 bleeding	 episode	 demonstrated	 a	 classical	 outcome	 of	
an	 anti‐VWF	 antibody	 upon	 re‐exposure	 to	 a	 VWF	 concentrate,	
with	the	neutralizing	antibody	developing	at	6	days	after	 initiating	
the	 treatment.	 In	 a	 sample	 obtained	 a	 few	weeks	 after	 the	 acute	
bleeding	episode,	no	VWF	antibody	could	be	 traced	 (ELISA‐based	
polyclonal	 anti‐human	 IgG	 antibody	 assay,	 kind	 assessment	 by	Dr	
Marc	Jacquemin).	Since	the	bleeding	episode,	the	patient	has	expe-
rienced	only	minor	bleeds,	mainly	epistaxis,	 treated	with	TXA.	An	
anti‐VWF:CB	antibody	titre	of	5	BU/mL,	without	anti‐VWF	IgG	or	
IgM	antibodies,	was	measured	as	part	of	the	International	Registries	
and	 Inhibitor	 Prospective	 (3WINTERS‐IPS)	 study,	 still	 some	 years	
after	 the	 last	 exposure	 to	 VWF‐containing	 replacement	 therapy.	
Currently,	the	lack	of	general	consensus	on	the	method	of	measur-
ing	anti‐VWF	antibodies	complicates	the	diagnostics.1	Recently,	due	
to	epistaxis,	the	patient	received	Haemate®	in	a	local	hospital	and	
developed	shortness	of	breath,	dizziness	and	itchiness	in	the	throat	
postinfusion,	resolving	after	discontinuation	of	the	treatment.
There	are	previous	reports	of	using	immuno‐modulative	treat-
ment	 as	 part	 of	 immunotolerance	 induction	 regimens	 in	 paediat-
ric	type	3	VWD	patients,	including	the	use	of	IVIG,	rituximab	and	
mycophenolate	mofetil.5,6	However,	 according	 to	our	 knowledge,	
our	case	report	describes	for	the	first	time,	how	IVIG	therapy	pre-
ceding	 pdVWF/FVIII	 infusion	 helped	 to	 resolve	 an	 acute	 bleed	
in	 a	 type	 3	 VWD	 patient	 with	 anti‐VWF	 antibodies.	 Similar	 ap-
proach	 has	 been	 reported	 in	AVWS	mainly	 in	 cases	 of	monoclo-
nal	 gammopathy,	whereas	 our	 patient	 had	 normal	 serum	 protein	
electrophoresis.	 Possible	 mechanisms	 of	 action	 for	 IVIG	 include	
elimination	of	circulating	 immune	complexes,	 inhibitory	effect	on	
the	antibody‐producing	cells	or	preventing	the	clearance	of	inhib-
itor‐VWF	complex	by	blocking	Fc	receptors,	but	other	mechanism	
may	also	be	involved.7
F I G U R E  1  Timelines	demonstrating	
the	treatment	of	a	life‐threatening	
GI	bleed	of	type	3	VWD	patient	with	
anti‐VWF	alloantibodies.	The	patient	
underwent	an	elective	colonoscopy	
with	biopsy	on	day	1,	leading	to	severe	
gastrointestinal	(GI)	bleeding	complication	
(day	3–11).	Following	intravenous	
immunoglobulin	(IVIG)	treatment	(arrows),	
the	bleed	resolved,	and	response	to	
VWF	treatment	was	achieved	.	Epistaxis	
further	prolonged	the	hospital	stay	
and	repeated	infusions	of	IVIG	on	days	
17	and	18	again	restored	VWF	and	
FVIII	levels.	VWF:Ag	=	VWF	antigen,	
VWF:RCo	=	VWF	ristocetin	cofactor	
activity,	pd	=	plasma‐derived	VWF/
FVIII,	pdVWF/FVIII1	=	Wilate®,	pdVWF/
FVIII2	=	Haemate®
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
0
25
50
75
100
125
150
175
200
225
250
275
300
IU
/d
L
VWF:RCo
FVIII
VWF:Ag
colonoscopy: x x x
GI bleed:
epistaxis:
pdVWF/FVIII1
pdVWF/FVIII2
pdFVIII
rFVIIa
IVIG 
infusion
DAY:
     |  3LETTER TO THE EDITOR
To	date,	 recommendations	 on	 the	 treatment	 of	VWD	patients	
who	 develop	 anti‐VWF	 antibodies	 are	 based	 on	 case	 reports	 and	
expert	opinions.	As	it	is	unknown	which	patients	with	anti‐VWF	al-
loantibodies	will	develop	severe	allergic	 reactions,	a	 review	article	
suggested	avoiding	VWF‐containing	concentrates.1	Both	rFVIII	and	
rFVIIa	have	been	used	to	treat	bleeds	and	manage	surgery	among	
these	 patients.8,9	 However,	 alternative	 treatment	 options	 should	
be	also	considered,	and	VWF‐containing	products	are	also	used.10 
rFVIIa	was	not	optimally	effective	in	our	case.	The	use	of	rFVIII	alone	
at	high	doses	of	continuous	infusion	corrects	FVIII	levels.	As	expert	
opinions	suggest	that	the	haemostatic	control	in	VWD	is	more	de-
pendent	on	FVIII	than	VWF	activity	levels,	treatment	with	rFVIII	ap-
pears	as	a	possible	future	strategy	for	treating	bleeds	in	our	patient.
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